Answers are grounded in this paper and cite their sources.
Palliative care is an essential component of comprehensive cancer management. However, in many low-resource settings, limited access to oncologic and surgical care leads patients to forgo potentially curative treatment and pursue palliation, even when their cancer is treatable. For palliative care programs operating with limited resources, understanding the organizational costs of providing symptom management alone versus facilitating access to cancer-directed treatment is critical for determining how best to allocate scarce healthcare resources. This study compares the organizational costs of providing palliative care with facilitated cancer-directed treatment (PC + T) versus palliative care alone (PC). We conducted a retrospective cohort study of 76 breast and cervical cancer patients receiving care from 2019 to 2021 at Rays of Hope Hospice Jinja, a palliative care center in Jinja, Uganda, which provides symptom management, psychosocial support, nutritional and financial assistance, and care coordination free to their patients. Total program cost, including facilitation for oncologic treatment (if applicable), transport, and labor, were analyzed. Groups were compared using Mann-Whitney U and Chi-squared or Fisher’s exact tests; differences are reported as Hodges-Lehmann estimates with 95% confidence intervals (CI). There were 43 PC patients and 33 PC + T patients. Median total cost per patient did not differ ($2,823 for PC vs. $3,182 for PC + T; difference $144, 95% CI −$1,655 to $1,481; p = 0.761). Compared with PC patients, PC + T patients remained enrolled longer (median 364 vs. 135 days; difference 119, 95% CI 33 to 237; p = 0.012), had fewer visits per month (0.76 vs. 1.30; difference − 0.65, 95% CI − 0.92 to − 0.29; p = 0.002) and a lower daily cost ($11.12 vs. $22.09; difference −$9.83, 95% CI −$16.92 to −$0.43; p = 0.038); only visit frequency remained significant after adjustment for multiple comparisons. Palliative care combined with facilitation to oncologic treatment was not associated with higher program cost than palliation alone, although this estimate was imprecise. Less frequent visits in the PC + T group may reflect that effective treatment limits disease progression. These findings suggest that integrating timely access to oncologic treatment within palliative care services may reduce patient morbidity and mortality without increasing overall program costs.
No takes yet. Share an insight, caveat, or question.
Travers et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: